Skip to main content

Medexprim and OpenRad announced a partnership to promote the secondary use of high-quality Real-World imaging data.

As a Real-World data specialist based in France, Medexprim deploys its software suite and services in an expanding network of leading European university hospitals. In compliance with GDPR, Medexprim solutions extract, aggregate, curate, enrich, and deidentify health data from multiple sources to deliver complex, regulatory-grade, multi-omics, and multicentric datasets to serve oncology, neurology, and cardiology academic or industrial research projects.

Located in London and Berlin, OpenRad delivers innovative radiology solutions for diagnostic imaging centres worldwide. It aims to power better diagnostics by delivering an integrated, patient-first experience to healthcare professionals and the wider research community.

This preferred partnership promotes the optimized secondary use of imaging data by healthcare professionals, industrials, and clinical researchers for analysis, teaching, and algorithm training. 

Romain Cazavan

Romain Cazavan, CEO of Medexprim: “Imaging is an objective element of tumor/cancer evolution according to treatments, and in particular when the analysis is aimed at a longitudinal follow-up. As such, today, 40% of clinical research questions require an analysis of the image produced during treatment administration.”

Dominic Kirkman, Chief Revenue Officer of OpenRad: “We are excited to have announced the partnership with Medexprim at our launch at RSNA. This collaboration enables our customers to collect, de-identify, and augment medical imaging data for secondary uses, such as clinical research, teaching, and AI algorithms training”.